Downloading...
Download

Biopharmaceutical

💊Celldex Therapeutics (CLDX) Analysis: Positive Phase 2 StudyKey Highlights: Positive Phase 2 Study: Celldex Therapeutics revealed positive outcomes from a Phase 2 study of Barzolvolimab, focusing on patients with moderate to severe chronic spontaneous urticaria (CSU) refractory. Well-Tolerated and Favorable Safety Profile: Barzolvolimab demonstrated general well-tolerance and exhibited a favorable safety profile in the study. Transformative Potential: CEO Anthony Marucci highlighted the potential transformative role of Barzolvolimab as a treatment option for patients suffering from CSU. Technical Analysis: Support Level: The analysis suggests a support level above $35.00-$36.00, indicating a potential floor for price movements. Upside Target: The upside target is set in the range of $56.00-$58.00, reflecting positive expectations for Celldex Therapeutics. #CelldexTherapeutics #CLDX #Biopharmaceutical #ClinicalStudy #StockAnalysis #Investing
NASDAQ:CLDXLong
by Richtv_official
Benitec Biopharma Inc. BNTC can explode anytime nowBenitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. (Source: Yahoo Finance) On April 15, 2020, the Company completed the re-domiciliation of the Company from Australia to the United States. As a result, the Company is now incorporated in the United States and its common stock is listed on Nasdaq. (Source: prnewswire.com) Market Cap 17.093M Please leave me a message if you want to test the buy and sell indicators that i am using.
NASDAQ:BNTCLong
by BuySellMarketMaker
2
Exclusive Licensing Agreement for GIAPREZA and XERAVA in EuropeLa Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe La Jolla to receive upfront cash payment of $22.5 million plus potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments Under the terms of the exclusive licensing agreement, La Jolla will be entitled to receive: (i) an upfront cash payment of $22.5 million; (ii) potential commercial milestone payments of up to $109.5 million; and (iii) double-digit tiered royalty payments based on net sales of GIAPREZA and XERAVA. In exchange, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the Territories. finance.yahoo.com
L
by AlenCiken
Biogen: Sell opportunity.BIIB closed the week around +25% as news regarding a crucial patent ruling came out in the company's favor. With the company's earnings also higher than the forecast, investors seem upbeat with the stock's dynamics. Even though the 1D chart turned overbought (RSI = 75.219, MACD = 6.690), on the weekly chart there is still a clear Resistance Zone at 370.00 - 389.00 which has been holding since 2016. The fact that the 1W candle pulled back making a big wick right after it entered the Resistance Zone, indicates that traders looked to book profits first. We see this as a strong sell opportunity towards at least the 267.00 Gap or even the 246.70 Symmetrical Support. ** If you like our free content follow our profile (www.tradingview.com) to get more daily ideas. ** Comments and likes are greatly appreciated.
NASDAQ:BIIBShort
by InvestingScope
Pfizer: Wide Moat and Interesting Ichimoku CloudsAfter the massive price drop at the end of July, Pfizer is pivoting its strategy selling Upjohn Unit to a new joint venture with Mylan and focusing on the new BioPharma business (mainly focusing on Ibrance, Xtandi, Inlyta, etc.). The new strategy provides Pfizer with a wide economic moat. I think the market currently undervalues the stock. The current price is above Ichimoku Green Cloud, and it coincides with the Lagging Span. I will expect a bullish progression of the price in the long term with the market correctly evaluating the new strategy. However, I see a risk of profit-taking in the next sessions anyhow, not so significant to let the stock test the upper support of the green cloud. Please, note that this analysis applies to long term positions. Don't forget to support this idea, if you liked it, and to follow me, here on TradingView. If you have another trading plan, please share in comments! Investing Fellow Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor.
NYSE:PFELong
by Investing_Fellow
Alexion: Trading around Volume Profile POCIf you like this idea, don't forget to hit the Like Button! Alexion business depends on patent-protected therapies in ultrarare and rare diseases of high unmet medical needs. While competitors are entering the market with biosimilars, Alexion still maintains an essential share of the market. My long term view is bullish. However, from a technical point of view, we are in a critical consolidation phase that started at the end of October 2019. The stock price is consolidating around $107.88 level. What to do now? I would wait for Alexion to exit the consolidation phase with a breakout. My signal is the break of the $116.61 important resistance. Look at the purple line in the graph (Developing POC) to monitor interesting volumes movements able to push up the price (in the chart Developing POC is overlapping the POC red line). I suggest to not go in with a trade immediately after the resistance breakout since Alexion presents high uncertainty. Thus wait for a confirmation green candle (daily). Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor.
A
by Investing_Fellow
DURECT CORP - NASDAQ: $DRRX FlaggingAfter breaking to higher ground a week ago on enormous volume, shares of DURECT CORP - NASDAQ:DRRX finds themselves consolidating the recent thrust in a Flag pattern on lower volume as we can observe from the Daily chart above. In addition, DRRX is now trading above all of its important moving averages 20/50/200 DMA's, which from a technical perspective, is healthy as well as constructive. Both investors/traders may want to continue to monitor the action closely in the days/weeks ahead as we believe that its only a matter of time before the stock comes up-and-out of its Flag with its sights set on greener pastures. Thus, investors/traders may want to put DRRX front-and-center on their radars as we're anticipating a potential move into the $1.40 - $1.60 zone (and potentially higher) should the stock pop out of its pattern within the days/weeks ahead. ****NOTE DURECT Corporation - NASDAQ:DRRX to Announce Second Quarter 2019 Financial Results on August 1, 2019 After Market Close ****
NASDAQ:DRRX
by OptionsGains
AIT THERAPEUTICS INC - NASDAQ: $AITB Waking UpAfter breaking to higher ground last month and subsequently consolidating/digesting the move, it appears that AIT THERAPEUTICS INC - NASDAQ:AITB is starting to wake-up once again as yesterday's action indicates when observing the Daily chart above. With the stock trading above all of its important moving averages 20/50/200 DMA's, AITB finds itself in a technically healthy posture. While there is no doubt that AITB is 'Thinly' traded, it certainly appears that buyers came into the stock yesterday and we may just witness some follow-through in the days/weeks ahead. Thus, both investors/traders may want to continue to monitor the action in AITB for additional clues/evidence with regards to potential further advance moving forward. Should AITB be capable of clearing the $6.25 hurdle at any point moving forward, we may just witness a move into the $9 - $10 zone.
A
by OptionsGains